In a Phase IIb trial enrolling 431 moderate to severe active SLE patients with inadequate responses to standard-of-care treatments, sifalimumab, a fully humanized anti-IFN-α IgG1κ monoclonal antibody, was effective in meeting the primary endpoint in determining the percentage of patients achieving an SLE responder index (SRI) response at week 52 (86). Here, IFNA2 is linked to systemic lupus erythematosus.